NAOMI: The trials and tribulations of implementing a heroin assisted treatment study in North America

Candice C Gartry, Eugenia Oviedo-Joekes, Nancy Laliberté, Martin T Schechter, Candice C Gartry, Eugenia Oviedo-Joekes, Nancy Laliberté, Martin T Schechter

Abstract

Background: Opioid addiction is a chronic, relapsing disease and remains a major public health challenge. Despite important expansions of access to conventional treatments, there are still significant proportions of affected individuals who remain outside the reach of the current treatment system and who contribute disproportionately to health care and criminal justice costs as well as to public disorder associated with drug addiction.The NAOMI study is a Phase III randomized clinical trial comparing injectable heroin maintenance to oral methadone. The study has ethics board approval at its Montréal and Vancouver sites, as well as from the University of Toronto, the New York Academy of Medicine and Johns Hopkins University.The main objective of the NAOMI Study is to determine whether the closely supervised provision of injectable, pharmaceutical-grade opioid agonist is more effective than methadone alone in recruiting, retaining, and benefiting chronic, opioid-dependent, injection drug users who are resistant to current standard treatment options.

Methods: The case study submitted chronicles the challenges of getting a heroin assisted treatment trial up and running in North America. It describes: a brief background on opioid addiction; current standard therapies for opioid addiction; why there is/was a need for a heroin assisted treatment trial; a description of heroin assisted treatment; the beginnings of creating the NAOMI study in North America; what is the NAOMI study; the science and politics of the NAOMI study; getting NAOMI started in Canada; various requirements and restrictions in getting the study up and running; recruitment into the study; working with the media; a status report on the study; and a brief conclusion from the authors' perspectives.

Results and conclusion: As this is a case study, there are no specific results or main findings listed. The case study focuses on: the background of the study; what it took to get the study started in Canada; the unique requirements and conditions of getting a site, and the study, approved; working with the media; recruitment into the study; a brief status report on the study; and a brief conclusion from the authors' perspectives.

Trial registration: ClinicalTrials.gov registration number: NCT00175357.

References

    1. Popova S, Rehm J, Fischer B. An overview of illegal opioid use and health services utilization in Canada. Public Health. 2006;120:320–8. doi: 10.1016/j.puhe.2005.09.010.
    1. Wall R, Rehm J, Fischer B, Brands B, Gliksman L, Stewart J, Medved W, Blake J. Social costs of untreated opioid dependence. J Urban Health. 2000;77:688–722. doi: 10.1007/BF02344032.
    1. March JC, Oviedo-Joekes E, Romero M. Drugs and social exclusion in ten European cities. Eur Addict Res. 2006;12:33–41. doi: 10.1159/000088581.
    1. Miller CL, Kerr T, Frankish JC, Spittal PM, Li K, Schechter MT, Wood E. Binge Drug Use Independently Predicts HIV Seroconversion Among Injection Drug Users: Implications for Public Health Strategies. Subst Use Misuse. 2006;41:199–210. doi: 10.1080/10826080500391795.
    1. Wood E, Li K, Palepu A, Marsh DC, Schechter MT, Hogg RS, Montaner JS, Kerr T. Sociodemographic disparities in access to addiction treatment among a cohort of Vancouver injection drug users. Subst Use Misuse. 2005;40:1153–67. doi: 10.1081/JA-200042287.
    1. Manzoni P, Brochu S, Fischer B, Rehm R. Determinants of Property Crime Among Illicit Opiate Users Outside of Treatment Across Canada. Deviant Behavior. 2006;27:351–76. doi: 10.1080/01639620600605705.
    1. Stenbacka M, Brandt L, Lettholm L. Leaving methadone maintenance treatment: the role of personality traits and psychiatric status. J Psychoactive Drugs. 2004;36:227–34.
    1. Bizzarri J, Rucci P, Vallotta A, Girelli M, Scandolari A, Zerbetto E, Sbrana A, Iagher C, Dellantonio E. Dual diagnosis and quality of life in patients in treatment for opioid dependence. Subst Use Misuse. 2005;40:1765–76. doi: 10.1080/10826080500260800.
    1. Disney E, Kidorf M, Kolodner K, King V, Peirce J, Beilenson P, Brooner RK. Psychiatric comorbidity is associated with drug use and HIV risk in syringe exchange participants. J Nerv Ment Dis. 2006;194:577–83. doi: 10.1097/01.nmd.0000230396.17230.28.
    1. Rehm J, Gnam W, Popova S, Baliunas D, Brochu S, Fischer B, Patra J, Sarnocinska-Hart A, Taylor B. The costs of alcohol, illegal drugs, and tobacco in Canada, 2002. J Stud Alcohol Drugs. 2007;68:886–95.
    1. Whynot E. Health impact of injection drug use and HIV in Vancouver. Report prepared by Dr Elizabeth Whynot on request of Vancouver's Medical Health Officer Dr John Blatherwick and Dr Anne Vogel and presented to the Vancouver Health Board on May 23, 1996. 1996.
    1. Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride. JAMA. 1965;193:646–50.
    1. Paulus I, Halliday R. Rehabilitation and the narcotic addict: results of a comparative methadone withdrawal program. Can Med Assoc J. 1967;96:655–9.
    1. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2003:CD002209.
    1. Farrell M, Ward J, Mattick R, Hall W, Stimson GV, des Jarlais D, Gossop M, Strang J. Methadone maintenance treatment in opiate dependence: a review. BMJ. 1994;309:997–1001.
    1. Amato L, Davoli M, A Perucci C, Ferri M, Faggiano F, P Mattick R. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat. 2005;28:321–9. doi: 10.1016/j.jsat.2005.02.007.
    1. Gowing L, Farrell M, Bornemann R, Sullivan L, Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2008:CD004145.
    1. Termorshuizen F, Krol A, Prins M, Geskus R, Brink W van den, van Ameijden EJ. Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam Cohort Study among drug users. Drug Alcohol Depend. 2005;79:231–40. doi: 10.1016/j.drugalcdep.2005.01.013.
    1. Roozen HG, Kerkhof AJ, Brink W Van Den. Experiences with an outpatient relapse program (community reinforcement approach) combined with naltrexone in the treatment of opioid-dependence: effect on addictive behaviors and the predictive value of psychiatric comorbidity. Eur Addict Res. 2003;9:53–8. doi: 10.1159/000068808.
    1. Esteban J, Gimeno C, Barril J, Aragones A, Climent JM, de la Cruz Pellin M. Survival study of opioid addicts in relation to its adherence to methadone maintenance treatment. Drug Alcohol Depend. 2003;70:193–200. doi: 10.1016/S0376-8716(03)00002-4.
    1. Appel PW, Ellison AA, Jansky HK, Oldak R. Barriers to enrollment in drug abuse treatment and suggestions for reducing them: opinions of drug injecting street outreach clients and other system stakeholders. Am J Drug Alcohol Abuse. 2004;30:129–53. doi: 10.1081/ADA-120029870.
    1. Kerr T, Marsh D, Li K, Montaner J, Wood E. Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver. Drug Alcohol Depend. 2005;80:329–35. doi: 10.1016/j.drugalcdep.2005.05.002.
    1. Krakowsk m, Smart RG. Social and Psychological Characteristics of Heroin Addicts Dropping Out of Methadone Treatment. Canadian Psychiatric Association Journal. 1974;19:41–7.
    1. Hser YI, Evans E, Huang D, Anglin DM. Relationship between drug treatment services, retention, and outcomes. Psychiatr Serv. 2004;55:767–74. doi: 10.1176/appi.ps.55.7.767.
    1. Perreault Michel, Rousseau Michel, Lauzon Pierre, Mercier Céline, Tremblay Isabelle, Héroux Marie-Christine. Determinants of Retention in a Canadian Low-Threshold Methadone Maintenance Program. Journal of Maintenance in the Addictions. 2007;3:37–51. doi: 10.1300/J126v03n02_06.
    1. Brink W van den, Hendriks VM, Blanken P, Koeter MW, van Zwieten BJ, van Ree JM. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. BMJ. 2003;327:310. doi: 10.1136/bmj.327.7410.310.
    1. Mino A, Page D, Dumont P, Broers B. Treatment failure and methadone dose in a public methadone maintenance treatment programme in Geneva. Drug Alcohol Depend. 1998;50:233–9. doi: 10.1016/S0376-8716(98)00035-0.
    1. Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. Heroin-assisted treatment for opioid dependence: Randomised controlled trial. Br J Psychiatry. 2007;191:55–62. doi: 10.1192/bjp.bp.106.026112.
    1. Mattick R, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008:CD002207.
    1. Information Canada. Canadian Government Commission of Inquiry into the Non-Medical Use of Drugs. Final Report. Ottawa. 1972.
    1. National Treatment Agency for Substance Misuse . Injectable heroin (and injectable methadone): potential roles in drug treatment. London, UK.: National Treatment Agency; 2003.
    1. Metrebian N, Carnwath Z, Mott J, Carnwath T, Stimson GV, Sell L. Patients receiving a prescription for diamorphine (heroin) in the United Kingdom. Drug Alcohol Rev. 2006;25:115–21. doi: 10.1080/09595230500537175.
    1. Rehm J, Gschwend P, Steffen T, Gutzwiller F, Dobler-Mikola A, Uchtenhagen A. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study. Lancet. 2001;358:1417–23. doi: 10.1016/S0140-6736(01)06529-1.
    1. Uchtenhagen A, Dobler-Mikola A, Steffen T, Gutzwiller F, Bläter R, Pfeifer S. Prescription of narcotics for heroin addicts: Main results of the Swiss National Cohort Study. New York: Karger; 1999.
    1. Steffen T, Christen S, Blattler R, Gutzwiller F. Infectious diseases and public health: risk-taking behavior during participation in the Swiss program for a medical prescription of narcotics (PROVE) Subst Use Misuse. 2001;36:71–89. doi: 10.1081/JA-100000229.
    1. Perneger TV, Giner F, del Rio M, Mino A. Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BMJ. 1998;317:13–8.
    1. Guttinger F, Gschwend P, Schulte B, Rehm J, Uchtenhagen A. Evaluating long-term effects of heroin-assisted treatment: the results of a 6-year follow-up. Eur Addict Res. 2003;9:73–9. doi: 10.1159/000068811.
    1. Ali R, Auriacombe M, Casas M, Cottler L, Farell M, Kleiber D, Kreuzer A, Ogborne A, Rehm J, Ward P. Report of the external panel on the evaluation of the Swiss scientific studies of medically prescribed narcotics to drug addicts. Geneva: WHO; 1999.
    1. Oviedo-Joekes E, Nosyk B, Brissette S, Chettiar J, Schneeberger P, Marsh DC, Krausz M, Anis A, Schechter MT. The North American Opiate Medication Initiative (NAOMI): Profile of Participants in North America's First Trial of Heroin-Assisted Treatment. J Urban Health. 2008;85:812–25. doi: 10.1007/s11524-008-9312-9.
    1. March JC, Oviedo-Joekes E, Perea-Milla E, Carrasco F. Controlled trial of prescribed heroin in the treatment of opioid addiction. J Subst Abuse Treat. 2006;31:203–11. doi: 10.1016/j.jsat.2006.04.007.
    1. Lintzeris N, Strang J, Metrebian N, Byford S, Lee S, Hallam C, Lee S, Zador D, RIOTT Group. Methodology for the Randomised Injecting Opioid Treatment Trial (RIOTT): evaluating injectable methadone and injectable heroin treatment versus optimised oral methadone treatment in the UK. Harm Reduct J. 2006;3:28. doi: 10.1186/1477-7517-3-28.
    1. Small DR, Drucker E. Policy Makers Ignoring Science Scientists Ignoring Policy: The Medical Ethical Challenges of Heroin Treatment. Harm Reduct J. 2006;3:16. doi: 10.1186/1477-7517-3-16.
    1. Plaza A, Oviedo-Joekes E, March JC, PEPSA Team. Nursing in an Intravenous Heroin Prescription Trial. Journal of Addiction Nursing. 2007;18:3–20.
    1. Bourgois P. Disciplining addictions: the bio-politics of methadone and heroin in the United States. Cult Med Psychiatry. 2000;24:165–95. doi: 10.1023/A:1005574918294.
    1. Federal Office of Public Health Heroin-assisted treatment/treatment with diacetylmorphine (HAT) in 2006. Switzerland. 2007.
    1. Farrell M, Hall W. The Swiss heroin trials: testing alternative approaches. BMJ. 1998;316:639.
    1. Oviedo-Joekes E, Nosyk B, Marsh D, Guh D, Brissette S, Gartry C, Krausz M, Anis A, Schechter MT. Scientific and political challenges in North America's first randomized controlled trial of heroin-assisted treatment for severe heroin addiction: Rationale and design of the NAOMI Study
    1. Firestone M, Fischer B. A qualitative exploration of prescription opioid injection among street-based drug users in Toronto: behaviours, preferences and drug availability. Harm Reduct J. 2008;5:30. doi: 10.1186/1477-7517-5-30.
    1. Statistics Canada. 2006. 2008.
    1. Cain J. Report of the Task Force into Illicit Narcotic Overdose Deaths in British Columbia. Victoria: Ministry of Attorney General; 1994.
    1. Baglole J. Vancouver's heroin 'fix' – injection facilities draw the ire of U.S. officials, others. Wall Street Journal (Eastern edition) 2003. p. D.8.
    1. Harper T. US Threatens Canada Over Marijuana Decriminalization. The Toronto Star. 2003.
    1. March JC, Oviedo-Joekes E, Romero M, Gomez M, Rodriguez S, Leon MI, Rodriguez C. The experimental drug prescription program in Andalusia [PEPSA]: procedure for recruiting participants: CAPTACION DE PARTICIPANTES EN EL PROGRAMA EXPERIMENTAL DE PRESCRIPCION DE ESTUPEFACIENTES EN ANDALUCIA (PEPSA) Gac Sanit. 2004;18:245–247. doi: 10.1157/13063102.
    1. Thomson CL, Morley KC, Teesson M, Sannibale C, Haber PS. Issues with recruitment to randomised controlled trials in the drug and alcohol field: a literature review and Australian case study. Drug Alcohol Rev. 2008;27:115–22. doi: 10.1080/09595230701829561.
    1. Haasen C, Vertheim U, Degkwitz P, Kuhn S, Ilse J, Lachmann A, et al. The German model project for heroin assisted treatment of opioid dependent patients. A multicentric, randomized, controlled treatment study. Germany: Centre for Interdisciplinary Addiction Research of Hamburg University (ZIS); 2006.
    1. Oviedo-Joekes E, Nosyk B, Brissette S, Chettiar J, Schneeberger P, Marsh D, Schechter MT. The North American Opiate Medication Initiative (NAOMI): Profile of participants in North America's first trial of heroin-assisted therapy. Journal of Urban Health. 2008
    1. Lawrence G, Bammer G, Chapman S. Sending the wrong signal': analysis of print media reportage of the ACT heroin prescription trial proposal, August 1997. Aust N Z J Public Health. 2000;24:254–64. doi: 10.1111/j.1467-842X.2000.tb01565.x.
    1. Bammer G, Dobler-Mikola A, Fleming PM, Strang J, Uchtenhagen A. The heroin prescribing debate: integrating science and politics. Science. 1999;284:1277–8. doi: 10.1126/science.284.5418.1277.
    1. Bammer G, Brink W van den, Gschwend P, Hendriks V, Rehm J. What can the Swiss and Dutch trials tell us about the potential risks associated with heroin prescribing? Drug Alcohol Rev. 2003;22:363–71. doi: 10.1080/0959523031000154517.
    1. Brink W van den, Hendriks VM, Blanken P, Huijsman IA, van Ree JM. Medical co-prescription of heroin: Two randomized controlled trials. Netherlands: Central Committee on the Treatment of Heroin Addicts (CCBH); 2002.
    1. Rehm J, Frick U, Hartwig C, Gutzwiller F, Gschwend P, Uchtenhagen A. Mortality in heroin-assisted treatment in Switzerland 1994–2000. Drug Alcohol Depend. 2005;79:137–43. doi: 10.1016/j.drugalcdep.2005.01.005.
    1. Fischer B, Oviedo-Joekes E, Blanken P, Haasen C, Rehm J, Schechter MT, Strang J, Brink W van den. Heroin-assisted Treatment (HAT) a Decade Later: A Brief Update on Science and Politics. J Urban Health. 2007;84:552–62. doi: 10.1007/s11524-007-9198-y.
    1. MacLean L. Federal government appeals Insite's exemption. The Hunts Ville Forester. 2008.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe